Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

Event Logistics

- PMLiVE

US and European Market Access for Medical Devices – Free Guide

We are delighted to announce that the second edition of our popular introductory guide: ‘Market access stakeholders and processes for medical devices in key European markets’ is now available. Our...

Petauri Evidence

Say Goodbye to Costly Delays – Origins’ Clinical Trial Participant Simulations Have the Answer!

Lack of Patient Involvement in Clinical Trial Designs Causes Major Issues Low recruitment and retention of clinical trials is a key issue faced by many clinical trials. These can lead...

Origins – The Patient Focused Specialists

- PMLiVE

FDA approves Samsung Bioepis’ Stelara biosimilar Pyzchiva for inflammatory conditions

The drug has been authorised to treat plaque psoriasis, psoriatic arthritis, Crohn’s disease and ulcerative colitis

- PMLiVE

AstraZeneca’s Imfinzi/Lynparza regimen recommended by CHMP to treat endometrial cancer

Almost 125,000 cases of endometrial cancer were diagnosed in Europe in 2022

- PMLiVE

Eli Lilly and Radionetics Oncology enter $140m radiopharma partnership

The strategic agreement also gives Lilly the exclusive right to acquire the biotech for $1bn

- PMLiVE

Roche announces CHMP recommendation for PiaSky in rare blood condition PNH

Paroxysmal nocturnal haemoglobinuria affects approximately 20,000 people worldwide

- PMLiVE

Almirall’s Ilumetri shown to improve and maintain well-being in plaque psoriasis patients

Nearly 77% of psoriasis patients report that the condition negatively affects their well-being

- PMLiVE

Find your brand’s edge, with dynamic competitive simulations

How the best teams in pharma stay at the top of their game

- PMLiVE

Johnson & Johnson’s Rybrevant granted EC approval for first-line NSCLC use

The drug was previously approved by the EU regulator for use after the failure of platinum-based therapy

- PMLiVE

Pfizer/BioNTech’s Omicron JN.1-adapted COVID-19 vaccine recommended by CHMP

The vaccine generated an improved response against several Omicron JN.1 sublineages

- PMLiVE

AbbVie announces CHMP recommendation for Tepkinly in follicular lymphoma

The blood cancer accounts for up to 30% of all non-Hodgkin lymphoma cases

- PMLiVE

Savara announces positive phase 3 results for molgramostim in rare lung disease

Autoimmune pulmonary alveolar proteinosis affects around one in every 150,000 people in the US

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links